Macrolide therapy of pneumonia: Is it necessary, and how does it help?

Current Opinion in Infectious Diseases

Volumn 29, Issue 2, 2016, Pages 212-217

  Restrepo, Marcos I ^a   Sole Violan, Jordi ^b   Martin Loeches, Ignacio ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Macrolides; Pneumonia; Treatment outcomes

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; ERYTHROMYCIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; NITRIC OXIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; ROXITHROMYCIN; TACROLIMUS; TELITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ASPIRATION PNEUMONIA; ASTHMA; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG MECHANISM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE ASSOCIATED PNEUMONIA; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; IMMUNOMODULATION; INFECTIOUS PNEUMONIA; INFLUENZA; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MEDICAL LITERATURE; META ANALYSIS (TOPIC); OUTPATIENT; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STREPTOCOCCUS PNEUMONIA; SUDDEN CARDIAC DEATH; VOLUME OF DISTRIBUTION; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PATHOLOGY; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CARDIOVASCULAR DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 84959900208     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000250     Document Type: Review

References (37)

1. Emmet O'Brien M, Restrepo MI, Martin-Loeches I. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respir Investig 2015;53:201-209. Recent comprehensive overview on the use of macrolide antibiotics for patients with CAP.
2. Cilloniz C, Albert RK, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 2015;191:1265-1272. Fourteen-year retrospective observational study from Barcelona evaluating the effect of macrolide resistance on the clinical presentation and outcomes on adult pneumococcal pneumonia patients.
3. Yamanaka Y, Tamari M, Nakahata T, Nakamura Y. Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun 2001;287:198-203.
4. Vazifeh D, Bryskier A, Labro MT. Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2000;44:511-521.
5. Arnold FW, Bordon J, Fernandez-Botran R, et al. Macrolide use and neutrophil function/cytokine levels in hospitalized patients with community-acquired pneumonia: a pilot study. Lung 2015. [Epub ahead of print] Pilot study on peripheral blood of patients with CAP testing neutrophil function measured by degranulation of secretory vesicles and specific granules, respiratory burst response and phagocytosis and 10 different cytokine levels of serum and sputum supernatants.
6. Yamamoto M, Kondo A, Tamura M, et al. Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis. Jpn J Thoracic Dis 1990;28:1305-1313.
7. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-1832.
8. Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003;97:844-850.
9. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-1842.
10. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management ofcommunity-acquiredpneumoniainadults. Clin Infect Dis 2007;44:S27-S72.
11. Eccles S, Pincus C, Higgins B, WoodheadM;Guideline Development Group. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ 2014;349:g6722.
12. Woodhead M, Blasi F, Ewig S, et al., Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections: full version. Clin Microbiol Infect 2011;17(Suppl 6):E1-E59.
13. Lim WS, Baudouin SV, George RC, et al., Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of communityacquired pneumoniain adults: update 2009. Thorax 2009;64(Suppl 3):iii1-iii55.
14. Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother 2014;69:1111-1118.
15. Laopaiboon M, Panpanich R, Swa Mya K. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2015;3:CD001954. This systematic review compared the effectiveness of azithromycin against amoxicillin or amoxicillin/clavulanic acid (amoxyclav) for the treatment of acute lower respiratory tract infections, such as acute bronchitis, pneumonia and acute exacerbation of chronic bronchitis.
16. Pakhale S, Mulpuru S, Verheij TJ, et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2014;10:CD002109.
17. Skalsky K, Yahav D, Lador A, et al. Macrolides vs.quinolones for communityacquired pneumonia: meta-analysis of randomized controlled trials. Clin Microbiol Infect 2013;19:370-378.
18. Nie W, Li B, Xiu Q. b-Lactam/macrolide dual therapy versus b-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1441-1446.
19. Garin N, Genné D, Carballo S, et al. b-lactam monotherapy vs b-lactammacrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014;174:1894-1901.
20. Postma DF, van Werkhoven CH, van Elden LJ, et al., CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312-1323. This study performed a cluster-randomized, crossover trial with strategies rotating in a 4-month period, a b-lactam strategy to the b-lactam macrolide strategy and fluoroquinolone strategies with respect to 90-day mortality in non-ICU-admitted patients with CAP.
21. Asadi L, Eurich DT, Gamble JM, et al. Impact of guideline-concordant antibiotics and macrolide/beta-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Clin Microbiol Infect 2013;19:257-264.
22. Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis. Int J Antimicrob Agents 2015;46:242-248. These authors performed a systematic review and meta-analysis of RCTs including adult inpatients and outpatients with CAP that compared treatment with any respiratory fluoroquinolone or macrolide administered as single agent with combination therapy of a β-lactam and either a fluoroquinolone or a macrolide (four separate comparisons).
23. So W, Crandon JL, Nicolau DP. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin susceptible Staphylococcus aureus. Intern Emerg Med 2015. [Epub ahead of print] These authors evaluated the outcomes of empiric ceftriaxone ± azithromycin in patients with MSSA pneumonia, as compared with S. pneumoniae.
24. Thompson AM, Thomas SE, Schafers SJ, et al. The role of azithromycin in healthcare-associated pneumonia treatment. J Clin Pharm Ther 2015; DOI:101111/jcpt12319. [Epub ahead of print] This article indicates that azithromycin should not be part of the standard empiric treatment of patients with HCAP.
25. McEvoy C, Micek ST, Reichley RM, et al. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia. Surg Infect (Larchmt) 2014;15:283-289.
26. Marumo S, Teranishi T, Higami Y, et al. Effectiveness of azithromycin in aspiration pneumonia: a prospective observational study. BMC Infect Dis 2014;14:685.
27. Kakeya H, Seki M, Izumikawa K, et al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, openlabel, randomized study. PLoS One 2014;9:e91293.
28. Valles J, Diaz E, Martín-Loeches I, et al. Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia. Med Intensiva 2015; S0210-S5691:00164-00173. This study evaluated the characteristics and outcomes of patients in the ICU with severe CAP over a 15-year surveillance period in a retrospective cohort.
29. Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and metaanalysis. Crit Care Med 2014;42:420-432.
30. Gattarello S, Borgatta B, Sole-Violan J, et al., Community-Acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014;146:22-31.
31. Gattarello S, Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe nonpneumococcal community-acquired pneumonia: a matched case-control study. Crit Care 2015;19:335. These authors report that in patients with severe nonpneumococcal CAP, early administration of antibiotics and the use of combination therapy were both associated with increased ICU survival.
32. Martin-Loeches I, LisboaT, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with communityacquired pneumonia. Intensive Care Med 2010;36:612-620.
33. Laserna E, Sibila O, Fernandez JF, et al. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia. Chest 2014;145:111 4-1120.
34. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-159.
35. Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest 2015;148:523-532. This interesting review article addresses the significant risk for development of inflammation-mediated acute cardiac events that may undermine the success of antimicrobial therapy including macrolides.
36. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014;311:2199-2208.
37. Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 2015;66:2173-2184. This comprehensive systematic review showed that the administration of macrolide antibiotics is associated with increased risk of sudden cardiac death or ventricular tachyarrhythmias and cardiovascular death but not increased all-cause tality.